Based on our previous findings that antioxidants, such as SOD2 and peroxiredoxin-1 (PRDX1), are elevated in dabrafenib resistant (DR) melanoma cells identified from a proteomics screen [7], we aimed to assess SOD2 and PRDX1 levels in BRAF and MEK inhibitor-resistant cells. This evidence concerns the gene MAP2K7 and melanoma.